Jump to content

Abediterol: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
Content deleted Content added
VisualWikitext
Abediterol is an experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease...
 
 
(34 intermediate revisions by 28 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Chembox
{{Drugbox
| ImageFile = Abediterol.svg
| Watchedfields = changed
| ImageSize =200px
| verifiedrevid =
| ImageAlt =
| IUPACName = (''R'')-5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1''H'')-one
| IUPAC_name = 5-[(1''R'')-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1''H'')-one
| image = Abediterol.svg
| OtherNames =
| width = 225
| Section1 = {{Chembox Identifiers

| CASNo = 915133-65-2
<!--Clinical data-->| tradename =
| CASNo_Ref = {{cascite|correct|}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| PubChem =
| pregnancy_US = <!-- A / B / C / D / X -->
| SMILES = FC(COCCCCCCNC[C@H](O)C1=C(C=CC(N2)=O)C2=C(O)C=C1)(F)C3=CC=CC=C3}}
| pregnancy_category =
| Section2 = {{Chembox Properties
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| C=25 | H=30 | F=2 | N=2 | O=4
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| Appearance =
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| Density =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| MeltingPt =
| routes_of_administration = Inhalation
| BoilingPt =
| legal_status = <!--Pharmacokinetic data-->
| Solubility = }}
| bioavailability =
| Section3 = {{Chembox Hazards
| protein_bound =
| MainHazards =
| metabolism =
| FlashPt =
| elimination_half-life = 24.3 hours<ref>{{cite journal | vauthors = Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S | title = First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist | journal = Journal of Clinical Pharmacology | volume = 54 | issue = 12 | pages = 1347–53 | date = December 2014 | pmid = 24989946 | doi = 10.1002/jcph.355 | s2cid = 20959248 }}</ref>
| Autoignition = }}
| excretion = <!--Identifiers-->
| Section5 = {{Chembox Pharmacology
| CAS_number = 915133-65-2
| AdminRoutes =
| ATC_prefix = None
| Bioavail =
| ATC_suffix =
| Metabolism =
| PubChem = 11962616
| HalfLife =
| IUPHAR_ligand = 9326
| ProteinBound =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| Excretion =
| DrugBank =
| Legal_status =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| Legal_US =
| ChemSpiderID = 10136846
| Legal_UK =
| UNII_Ref = {{fdacite|correct|FDA}}
| Legal_AU =
| UNII = QXA167CM6F
| Legal_CA =
| KEGG_Ref = {{keggcite|correct|kegg}}
| PregCat =
| KEGG = D10219
| PregCat_AU =
| ChEBI = 142077
| PregCat_US = }}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 3039530

<!--Chemical data-->| C = 25
| H = 30
| F = 2
| N = 2
| O = 4
| smiles = FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SFYAXIFVXBKRPK-QFIPXVFZSA-N
}}
}}


'''Abediterol''' ([[International Nonproprietary Name|INN]]<ref>[http://whqlibdoc.who.int/druginfo/24_4_2010_INN104.pdf WHO Drug Information, Vol. 24, No. 4, 2010]</ref>) is an experimental drug candidate for the treatment of [[asthma]] and [[chronic obstructive pulmonary disease]]. It is currently under [[drug development|development]] by the Spanish pharmaceutical company [[Almirall]] and is in Phase II clinical trials.<ref>[http://www.almirall.com/webcorp2/cda/ImD_03_02.jsp Product development pipeline], [[Almirall]]</ref> It acts as a [[muscarinic antagonist]] and a [[Beta2-adrenergic agonist|β<sub>2</sub>-adrenergic agonist]].<ref>{{cite patent|WO|2006122788}}</ref><ref>{{cite patent|WO|2010094484}}</ref>
'''Abediterol''' ([[International Nonproprietary Name|INN]];<ref>{{cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104|journal=WHO Drug Information|date=2010|volume=24|issue=1|page=352|url=https://www.who.int/medicines/publications/druginformation/issues/PL-104.pdf|access-date=25 March 2016}}</ref> development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of [[asthma]] and [[chronic obstructive pulmonary disease]] (COPD), but it has never been marketed.


==References==
==History==
Abediterol was under [[drug development|development]] by the Spanish pharmaceutical company [[Almirall]] and reached [[Phases of clinical research#Phase II|Phase II]] clinical trials,<ref>[http://www.almirall.com/webcorp2/cda/ImD_03_02.jsp Product development pipeline], [[Almirall]]</ref><ref>{{cite web|title=AdisInsight: Abediterol|url=http://adisinsight.springer.com/drugs/800026746|website=Adis Insight|publisher=Springer International Publishing AG|access-date=25 March 2016}}</ref> but was discontinued in 2021.<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800026746 | title = Abediterol |website=Adis Insight |publisher=Springer International Publishing AG |access-date= 6 February 2024}}</ref> Its coformulation with [[mometasone furoate]] also progressed to Phase II clinical trials, but was discontinued in 2019.<ref>{{cite web|title=AdisInsight: Abediterol/mometasone|url=http://adisinsight.springer.com/drugs/800033847|website=Adis Insight|publisher=Springer International Publishing AG |access-date= 6 February 2024}}</ref>
{{reflist}}


==Mechanism of action==
Abediterol acts as a dual [[Beta2-adrenergic agonist|β<sub>2</sub> adrenergic agonist]]<ref>{{Cite web|title=Espacenet - Bibliographic data|url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=2006122788&KC=&FT=E&locale=en_EP|access-date=2021-05-07|website=worldwide.espacenet.com}}</ref><ref>{{Cite web|title=Espacenet - Bibliographic data|url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=2010094484&KC=&FT=E&locale=en_EP|access-date=2021-05-07|website=worldwide.espacenet.com}}</ref> and [[muscarinic antagonist]] and is classified as an [[Long-acting beta-adrenoceptor agonist|ultra-long-acting β<sub>2</sub> agonist]] (ultra-LABA).<ref>{{cite journal | vauthors = Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S | title = Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma | journal = Respiratory Medicine | volume = 108 | issue = 10 | pages = 1424–9 | date = October 2014 | pmid = 25256258 | doi = 10.1016/j.rmed.2014.08.005 | url = http://www.resmedjournal.com/article/S0954-6111(14)00287-X/pdf | doi-access = free }}</ref>


== References ==
{{pharma-stub}}
{{reflist|2}}


{{Asthma and copd rx}}
[[Category:Organofluorides]]
{{Adrenergic receptor modulators}}
[[Category:Quinolones]]
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Long-acting beta2-adrenergic agonists]]
[[Category:Muscarinic antagonists]]
[[Category:Muscarinic antagonists]]
[[Category:Beta-adrenergic agonists]]
[[Category:Organofluorides]]
[[Category:2-Quinolones]]
[[Category:Hydroxyarenes]]
[[Category:Phenylethanolamines]]
[[Category:Abandoned drugs]]


{{respiratory-system-drug-stub}}

Latest revision as of 10:25, 21 October 2024

Abediterol
Clinical data
Routes of
administration		Inhalation
ATC code
  • None
Pharmacokinetic data
Elimination half-life24.3 hours[1]
Identifiers
  • 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H30F2N2O4
Molar mass460.522 g·mol−1
3D model (JSmol)
  • FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
  • InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 checkY
  • Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N checkY

Abediterol (INN;[2] development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

History

[edit]

Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials,[3][4] but was discontinued in 2021.[5] Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.[6]

Mechanism of action

[edit]

Abediterol acts as a dual β2 adrenergic agonist[7][8] and muscarinic antagonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA).[9]

References

[edit]
  1. ^ Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist". Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355. PMID 24989946. S2CID 20959248.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.
  3. ^ Product development pipeline, Almirall
  4. ^ "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.
  5. ^ "Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.
  6. ^ "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 6 February 2024.
  7. ^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
  8. ^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
  9. ^ Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–9. doi:10.1016/j.rmed.2014.08.005. PMID 25256258.


Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Abediterol&oldid=1252437307"